Shandong Puhua Pharmaceutical Co., Ltd. announced that it will receive equity funding from returning investor, Beijing Konruns Pharmaceutical Co.,Ltd. (SHSE:603590) on January 17, 2019. The transaction has been approved at the 14th session of the 2nd directorate meeting of the investor. On closing, the investor will continue to retain its 100% stake in the company.